Background: Mutations of fibroblast growth factor receptor 2 (FGFR2) account for a higher proportion of genetic cases of craniosynostosis than any other gene, and are associated with a wide spectrum of severity of clinical problems. Many of these mutations are highly recurrent and their associated features well documented. Crouzon syndrome is typically caused by heterozygous missense mutations in the third immunoglobulin domain of FGFR2.
Background
Craniosynostosis defines the premature fusion of the cranial sutures and has an overall prevalence of 1 in 2100-2300 live births [1, 2] . Nearly one quarter of craniosynostosis has a genetic aetiology [3, 4] ; there is considerable genetic heterogeneity and frequent phenotypic overlap between different syndromes. Genes encoding three members of the fibroblast growth factor receptor family (FGFR1, FGFR2 and FGFR3) are commonly mutated in individuals with craniosynostosis. Heterozygous mutations in FGFR2, which are frequently recurrent, account for~28% of genetic cases [4] and cause Crouzon [5, 6] , Pfeiffer [7] [8] [9] , Apert [10] , Beare-Stevenson [11] and bent bone dysplasia [12] syndromes. All involve synostosis of the coronal and other cranial sutures, a distinctive "crouzonoid" craniofacial appearance (comprising hypertelorism, exorbitism, prominent nose, and midface hypoplasia), but differ in the presence and extent of abnormalities of the hands and feet, other skeletal manifestations and dermatological features [13, 14] .
FGFR2, like the other members of the FGFR family, comprises an extracellular ligand-binding region (composed of three immunoglobulin-like domains), a single transmembrane peptide and a cytoplasmic tyrosine kinase domain. Mutually exclusive alternative splicing of exons IIIb and IIIc gives rise to epithelial and mesenchymal isoforms (FGFR2b and FGFR2c) respectively [15] . These alternative extracellular domains interact with different repertoires of fibroblast growth factors (FGFs) to regulate downstream processes such as proliferation, differentiation and cell migration [16] .
Here we describe two families heterozygous for the same, previously unreported apparently synonymous variant in FGFR2 [p.(Pro361Pro)], although caused by differing nucleotide substitutions. The mutation carriers in both families exhibit features of mild Crouzon syndrome, and a minority required craniofacial surgery. We propose that this variant is in fact pathogenic and demonstrate the generation of abnormal cDNA products resulting from incorrect splicing of exon IIIc in the mutant allele. This finding highlights the challenges posed in interpreting such synonymous variants when providing genetic counselling for affected families.
Case presentations

Family 1
Individual III-1 ( Figure 1A ) was born after a normal pregnancy and was referred for craniofacial assessment at two years of age because prominent eyes and a head tilt. Her father II-1 ( Figure 1B ), grandmother I-1 and two deceased uncles were all said to have a similar appearance with prominent staring eyes, but had not required any surgery. She had an occipitofrontal circumference (OFC) of 50 cm (+1.1 SD) and was noted to have a mildly crouzonoid appearance, with slight exorbitism and midface retrusion. In view of the mild crouzonoid features, sequencing of FGFR2 exons IIIa and IIIc was requested. This demonstrated a heterozygous c.1083A>G [p. (Pro361Pro)] variant within exon IIIc, which was also present in II-1 and I-1.
Computed tomography (CT) of the skull of individual III-1 at the age of 2.8 years demonstrated right lambdoid and occipitomastoid synostosis, all other major cranial sutures being patent. Ophthalmological review identified slightly reduced visual acuity and a latent divergent squint with slight left hypophoria. The patient is now four years old and has not undergone any surgical intervention, as she has a good overall head shape with no major midface retrusion, is making good developmental progress, and has no features to suggest significant intracranial restriction.
Family 2
The male proband (III-2 in Figure 1C ), born after an uneventful pregnancy, was referred for craniofacial assessment at the age of three months. Physical examination showed a mild cloverleaf skull with temporal bulging and reduced OFC (36 cm; −2.2 SD), hypertelorism, and severe exorbitism mainly at the infra-orbital level. Skull X-ray and CT showed pansynostosis and multiple craniolacunae, with no intracerebral anomalies.
Owing to the severe peri-orbital features and the absence of deformations of the upper and lower extremities a clinical diagnosis of Crouzon syndrome was suggested. The patient's mother, grandmother and several cousins were reported to show mild facial features also suggestive of this diagnosis.
The proband underwent fronto-orbital advancement at the age of five months. Since the occiput was still severely flattened and both lambdoid sutures were fused, occipital craniotomy and remodelling was performed at the age of twelve months. Clumsiness and motor delay were first noted aged 18 months; psychological testing at the age of 12.8 years gave scores for non-verbal intelligence of 80 (SON-R) and visual-motor integration of 81. Clonidine was prescribed due to high distractibility and he underwent special education. During childhood, the exorbitism increased requiring further orbital advancement and cranial vault remodelling at the age of eight years. Several deciduous and permanent teeth were extracted because of Class III malocclusion and dental crowding.
Genetic testing of FGFR2 was performed, identifying the heterozygous point mutation c.1083A>T [p.(Pro361Pro); Figure 2A ]. This variant was also present in his mother II-1.
Independently of these events, a second patient (III-1) was referred to the same clinic at the age of ten years with a scaphocephalic head shape. He had previously undergone vault remodelling at the age of 16 months owing to bicoronal synostosis. At the time of referral, he had an occipito-frontal circumference of 48.5 cm (−2.8 SD), hypertelorism and severe exorbitism. In addition, he had mild maxillary hypoplasia and both 2nd premolars of the lower jaw were absent. Ophthalmic examination showed myopia with divergent strabismus of the right eye associated with reduced visual acuity. A monobloc procedure without distraction (Le Fort III and an advancement of the forehead) was performed.
Due to the severe peri-orbital features a diagnosis of Crouzon syndrome was suggested. Analysis of FGFR2 identified the heterozygous point mutation c.1083A>T [p. (Pro361Pro)]. His father, grandmother and greatgrandmother had a similar craniofacial appearance. Based on the pedigree analysis, it is evident that III-1 and III-2 are third cousins and that the FGFR2 mutation present in these two branches is identical by descent ( Figure 1C) . Apart from III-1 and III-2, none of the other affected family members had undergone craniofacial surgery. 
Materials and methods
Ethics approval for the study was obtained from NRES Committee London -Riverside (09/H0706/20) and the Medical Ethical Committee of the Erasmus University Medical Center Rotterdam (MEC-2013-547). Venous blood was collected into PAXgene Blood RNA tubes (Qiagen) from individuals II-1 (Family 1) and III-1 (Family 2), and RNA was extracted according to the associated protocol. cDNA was synthesized using the Fermentas RevertAid First-Strand Synthesis kit with random hexamer primers according to the manufacturer's instructions.
cDNA was amplified using a forward primer in FGFR2 exon IIIa (5′-TCGGAGGAGACGTAGAGTTTGTCTG C-3′) used in combination with a reverse primer in exon 11 (encoding the transmembrane (TM) domain; 5′-TGT TACCTGTCTCCGCAGGGGGATA-3′). DNA bands were cut out and gel purified using the Q-Spin gel extraction kit (Geneflow). Dideoxy sequencing was carried out on the resulting DNA products. The resulting cDNA products were numbered according to NCBI Reference Sequence: NM_000141.4.
Results
The synonymous variants c.1083A>G and c.1083A>T occur at the −2 position of the 5′ (donor) splice site of FGFR2 exon IIIc (Figure 2A ). The neural network splice site predictor (http://www.fruitfly.org/seq_tools/splice.html) generates a score for the wild type donor of 0.88, which is reduced to 0.37 by the A>G transition, and to 0.19 by the A>T transversion. In these circumstances, use of a cryptic splice site (score 0.84) within exon IIIc, 51 nucleotides upstream from the end of the exon, is expected based on analysis of a previous mutation c.1084+3A>G [17] . This would lead to an in-frame deletion of 17 amino acids.
Amplification of cDNA from individuals heterozygous for either the FGFR2 c.1083A>G or the c.1083A>T variants demonstrated the presence of two additional bands, not present in the wild type control, at approximately 430 bp and 330 bp ( Figure 2B) . Sequencing of the normal 479 bp product from these individuals showed complete absence of the mutant allele (illustrated in Figure 2C for II-1 from Family 1), indicating that both mutations abolish use of the normal exon IIIc donor splice site. Sequencing of the~430 bp product confirmed that the cryptic splice donor within exon IIIc was preferred in the mutant allele ( Figure 2D) , while the~330 bp product demonstrated complete skipping of exon IIIc ( Figure 2E ).
Conclusions
In humans there is a consensus sequence around the 5′ splice donor site: A, C or T, AG / gtaagt (where / indicates the exon-intron boundary). Mutations of the consensus A at the penultimate nucleotide of the exon have been associated previously with loss of splicing at the donor site [18, 19] . Other mutations near the FGFR2 exon IIIc splice donor site have also been described (Table 1) , all associated with a mild Crouzon phenotype. It is likely that the p.(Ala362Ser) substitution [20] in fact exerts its pathogenic effect via the G>T transversion at the −1 position in the exon, rather than as a missense substitution, but this was not tested experimentally.
In the cases reported here, the wild type splice donor site is abolished by the A>G or A>T mutations at the −2 position from the intron, leading to the cryptic site being preferred. The apparently greater amount of mutant cDNA products associated with the A>T mutation appears to correlate both with the greater predicted disruption of the splice site and with the more severe phenotype in clinically affected individuals from Family 2 compared with Family 1. However, since the A>G mutation did not support use of the normal exon IIIc donor splice site ( Figure 2C ), other explanations for these differences are possible, such as differing proportions of cell types in the blood samples analysed, and/or differences in genetic background.
Utilisation of the cryptic donor would lead to an inframe deletion of the last 17 amino acids of exon IIIc (p.Gly345_Pro361del), including four residues that form specific contacts with the ligand FGF2 [25] . However as craniosynostosis-causing FGFR mutations function in a [24] constitutively active dominant manner [26] , it is also likely that in these individuals a mutant protein is formed which is prone to forming covalently-linked dimers [26] , leading to variable features of Crouzon syndrome. Our case reports document the range of phenotypic consequences associated with these particular mutations. Whilst a mild crouzonoid phenotype was generally evident, only a minority of individuals developed overt craniosynostosis requiring calvarial surgery. Orthodontic problems may also occur but these were not fully documented in our study. The causes of the clinical variability are unknown, although one potential factor may be the extent of intrauterine fetal head constraint [27] .
In conclusion, mutations near the FGFR2 exon IIIc splice sites should be carefully evaluated as to whether they may be pathogenic, even if they are synonymous or outside the canonical AG/GT splice acceptor/donor sequences. In particular, the mutations described here are associated with variable Crouzon syndrome features and affected families should be counselled as such.
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